ArticleDiscover oncology2026
Predictive value of apparent diffusion coefficient, plasma levels of placental growth factor and glial fibrillary acidic protein, and their combinations for patients with recurrent glioblastoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveGlioblastoma (GB) is the deadliest primary brain tumor, largely due to inevitable recurrence of the disease after partial surgical resection or resistance to drug treatments. The study aimed to evaluate the predictive values of apparent diffusion coefficient (ADC) from diffusion-weighted imaging (DWI), plasma levels of placental growth factor (PGF) and glial fibrillary acidic protein (GFAP), and their combination in GB recurrence.
methodsThe study included 200 patients diagnosed with GB consisting of 136 with tumor recurrence and 64 without. DWI examinations and PGF and GFAP measurements in the plasma were performed preoperatively.
resultsThe patients with recurrent disease exhibited a lower value of ADC with higher plasma PGF and GFAP levels than those with non-recurrence. The results of Pearson correlation analysis suggested the ADC shared negative correlations with plasma levels of PGF and GFAP in patients with recurrent GB. The plasma level of PGF was also found to be positively correlated with the plasma level of GFAP in patients with recurrent GB. The ADC, plasma levels of PGF and GFAP in predicting recurrent GB presented AUC: 0.75, 0.85, and 0.82, respectively. Combined analysis of two of three to evaluate the prediction showed AUCs of 0.98 (ADC and PGF), 0.96 (ADC and GFAP), and 0.84 (PGF and GFAP). Combined analysis of ADC and plasma PGF, ADC and plasma GFAP, PGF and GFAP to evaluate the prediction showed AUCs of 0.98, 0.96, and 0.84, respectively. Combined analysis of three of them to evaluate the prediction showed AUC as 0.98.
conclusionThe study demonstrates that combined ADC and plasma PGF showed a similar predictive value in recurrent GB after standard treatment as combined ADC, plasma PGF and GFAP together. Considering limited sample size and lack of more sample types in this study, additional value of plasma GFAP in predicting recurrent GB should be further investigated in larger-scale population or different sample sources.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.